These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 36613492)

  • 1. Understanding Carbohydrate Metabolism and Insulin Resistance in Acute Intermittent Porphyria.
    Solares I; Jericó D; Córdoba KM; Morales-Conejo M; Ena J; Enríquez de Salamanca R; Fontanellas A
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucose metabolism during fasting is altered in experimental porphobilinogen deaminase deficiency.
    Collantes M; Serrano-Mendioroz I; Benito M; Molinet-Dronda F; Delgado M; Vinaixa M; Sampedro A; Enríquez de Salamanca R; Prieto E; Pozo MA; Peñuelas I; Corrales FJ; Barajas M; Fontanellas A
    Hum Mol Genet; 2016 Apr; 25(7):1318-27. PubMed ID: 26908609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical characterization of porphobilinogen deaminase-deficient mice during phenobarbital induction of heme synthesis and the effect of enzyme replacement.
    Johansson A; Möller C; Fogh J; Harper P
    Mol Med; 2003; 9(9-12):193-9. PubMed ID: 15208740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria.
    D'Avola D; López-Franco E; Sangro B; Pañeda A; Grossios N; Gil-Farina I; Benito A; Twisk J; Paz M; Ruiz J; Schmidt M; Petry H; Harper P; de Salamanca RE; Fontanellas A; Prieto J; González-Aseguinolaza G
    J Hepatol; 2016 Oct; 65(4):776-783. PubMed ID: 27212246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Porphobilinogen deaminase over-expression in hepatocytes, but not in erythrocytes, prevents accumulation of toxic porphyrin precursors in a mouse model of acute intermittent porphyria.
    Unzu C; Sampedro A; Mauleón I; Vanrell L; Dubrot J; de Salamanca RE; González-Aseguinolaza G; Melero I; Prieto J; Fontanellas A
    J Hepatol; 2010 Mar; 52(3):417-24. PubMed ID: 19815305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nutritional Interventions with
    Longo M; Jericó D; Córdoba KM; Riezu-Boj JI; Urtasun R; Solares I; Sampedro A; Collantes M; Peñuelas I; Moreno-Aliaga MJ; Ávila MA; Di Pierro E; Barajas M; Milagro FI; Dongiovanni P; Fontanellas A
    Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver Transplantation for Acute Intermittent Porphyria: Biochemical and Pathologic Studies of the Explanted Liver.
    Yasuda M; Erwin AL; Liu LU; Balwani M; Chen B; Kadirvel S; Gan L; Fiel MI; Gordon RE; Yu C; Clavero S; Arvelakis A; Naik H; Martin LD; Phillips JD; Anderson KE; Sadagoparamanujam VM; Florman SS; Desnick RJ
    Mol Med; 2015 Jun; 21(1):487-95. PubMed ID: 26062020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic messenger RNA as an etiological treatment for acute intermittent porphyria.
    Jiang L; Berraondo P; Jericó D; Guey LT; Sampedro A; Frassetto A; Benenato KE; Burke K; Santamaría E; Alegre M; Pejenaute Á; Kalariya M; Butcher W; Park JS; Zhu X; Sabnis S; Kumarasinghe ES; Salerno T; Kenney M; Lukacs CM; Ávila MA; Martini PGV; Fontanellas A
    Nat Med; 2018 Dec; 24(12):1899-1909. PubMed ID: 30297912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenoviral-mediated expression of porphobilinogen deaminase in liver restores the metabolic defect in a mouse model of acute intermittent porphyria.
    Johansson A; Nowak G; Möller C; Blomberg P; Harper P
    Mol Ther; 2004 Aug; 10(2):337-43. PubMed ID: 15294180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of volatile anaesthetics on heme metabolism in a murine genetic model of Acute Intermittent Porphyria. A comparative study with other porphyrinogenic drugs.
    Ruspini SF; Zuccoli JR; Lavandera JV; Martínez MDC; Oliveri LM; Gerez EN; Batlle AMDC; Buzaleh AM
    Biochim Biophys Acta Gen Subj; 2018 Jun; 1862(6):1296-1305. PubMed ID: 29476795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatocyte transplantation ameliorates the metabolic abnormality in a mouse model of acute intermittent porphyria.
    Yin Z; Wahlin S; Ellis EC; Harper P; Ericzon BG; Nowak G
    Cell Transplant; 2014; 23(9):1153-62. PubMed ID: 23582197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homozygous hydroxymethylbilane synthase knock-in mice provide pathogenic insights into the severe neurological impairments present in human homozygous dominant acute intermittent porphyria.
    Yasuda M; Gan L; Chen B; Yu C; Zhang J; Gama-Sosa MA; Pollak DD; Berger S; Phillips JD; Edelmann W; Desnick RJ
    Hum Mol Genet; 2019 Jun; 28(11):1755-1767. PubMed ID: 30615115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal failure affects the enzymatic activities of the three first steps in hepatic heme biosynthesis in the acute intermittent porphyria mouse.
    Unzu C; Sampedro A; Sardh E; Mauleón I; Enríquez de Salamanca R; Prieto J; Salido E; Harper P; Fontanellas A
    PLoS One; 2012; 7(3):e32978. PubMed ID: 22412963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correction of the biochemical defect in porphobilinogen deaminase deficient cells by non-viral gene delivery.
    Johansson A; Möller C; Harper P
    Mol Cell Biochem; 2003 Aug; 250(1-2):65-71. PubMed ID: 12962144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma porphobilinogen as a sensitive biomarker to monitor the clinical and therapeutic course of acute intermittent porphyria attacks.
    Sardh E; Harper P; Andersson DE; Floderus Y
    Eur J Intern Med; 2009 Mar; 20(2):201-7. PubMed ID: 19327613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular and biochemical studies of acute intermittent porphyria in 196 patients and their families.
    Kauppinen R; von und zu Fraunberg M
    Clin Chem; 2002 Nov; 48(11):1891-900. PubMed ID: 12406973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ALAD Inhibition by Porphobilinogen Rationalizes the Accumulation of δ-Aminolevulinate in Acute Porphyrias.
    San Juan I; Pereira-Ortuzar T; Cendoya X; Laín A; To-Figueras J; Mateos B; Planes FJ; Bernardo-Seisdedos G; Mato JM; Millet O
    Biochemistry; 2022 Nov; 61(21):2409-2416. PubMed ID: 36241173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variations in porphobilinogen and 5-aminolevulinic acid concentrations in plasma and urine from asymptomatic carriers of the acute intermittent porphyria gene with increased porphyrin precursor excretion.
    Floderus Y; Sardh E; Möller C; Andersson C; Rejkjaer L; Andersson DE; Harper P
    Clin Chem; 2006 Apr; 52(4):701-7. PubMed ID: 16497943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutting-Edge Therapies and Novel Strategies for Acute Intermittent Porphyria: Step-by-Step towards the Solution.
    Longo M; Paolini E; Meroni M; Dongiovanni P
    Biomedicines; 2022 Mar; 10(3):. PubMed ID: 35327450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Porphobilinogen deaminase deficiency in mice causes a neuropathy resembling that of human hepatic porphyria.
    Lindberg RL; Porcher C; Grandchamp B; Ledermann B; Bürki K; Brandner S; Aguzzi A; Meyer UA
    Nat Genet; 1996 Feb; 12(2):195-9. PubMed ID: 8563760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.